Hepion Pharmaceuticals, Inc. (HEPA) Earnings History
Annual and quarterly earnings data from 2012 to 2025
Loading earnings history...
HEPA EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
HEPA Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export HEPA earnings history in CSV or JSON format
Free sign-in required to download data
Hepion Pharmaceuticals, Inc. (HEPA) Earnings Overview
As of May 8, 2026, Hepion Pharmaceuticals, Inc. (HEPA) reported trailing twelve-month net income of -$8M, reflecting +99.2% year-over-year growth. The company earned $-0.88 per diluted share over the past four quarters.
Looking at the long-term picture, HEPA's historical earnings data spans multiple years. The company achieved its highest annual net income of -$842,970 in fiscal 2012.
Hepion Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including MDGL (-$309M net income, -30.1% margin), AKRO (-$293M net income), HALO ($317M net income, 22.7% margin), HEPA has comparable earnings metrics. Compare HEPA vs MDGL →
HEPA Earnings vs Peers
Earnings metrics vs comparable public companies
HEPA Historical Earnings Data (2012–2025)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$8M | +37.3% | -$4M | $-0.88 | - | - |
| 2024 | -$13M | +73.0% | -$19M | $-107.35 | - | - |
| 2023 | -$49M | -15.9% | -$48M | $-616.07 | - | - |
| 2022 | -$42M | -29.0% | -$45M | $-594.75 | - | - |
| 2021 | -$33M | -60.8% | -$30M | $-465.52 | - | - |
| 2020 | -$20M | -189.2% | -$20M | $-2103.70 | - | - |
| 2019 | -$7M | +25.5% | -$8M | $-6108.07 | - | - |
| 2018 | -$9M | +37.1% | -$15M | $-97353.00 | - | - |
| 2017 | -$15M | -0.9% | -$21M | $-106400.00 | - | - |
| 2016 | -$15M | +12.4% | -$21M | $-3373.93 | - | - |
See HEPA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs HEPA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare HEPA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonHEPA — Frequently Asked Questions
Quick answers to the most common questions about buying HEPA stock.
Is HEPA growing earnings?
HEPA EPS is $-0.88, with earnings growth accelerating to +99.2%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-8M.
What are HEPA's profit margins?
Hepion Pharmaceuticals, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are HEPA's earnings?
HEPA earnings data spans 2012-2025. The accelerating earnings trend is +99.2% YoY. Historical data enables comparison across business cycles.